Jonathon W Senefeld, Stephen A Klassen, Shane K Ford, Katherine A Senese, Chad C Wiggins, Bruce C Bostrom, Michael A Thompson, Sarah E Baker, Wayne T Nicholson, Patrick W Johnson, Rickey E Carter, Jeffrey P Henderson, William R Hartman, Liise-Anne Pirofski, R Scott Wright, De Lisa Fairweather, Katelyn A Bruno, Nigel S Paneth, Arturo Casadevall, Michael J Joyner
In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID-19), including among patients with innate or acquired immunosuppression. However, the association between COVID-19-associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched-control registry study of 143 COVID-19 patients with hematological malignancies, and 51 case reports and 23 case series representing 238 COVID-19 patients with immunosuppression...
August 2021: Transfusion